Company intelligence / Profile preview
Asana BioSciences, LLC
Bridgewater, New Jersey, United Statesasanabio.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Asana BioSciences has multiple clinical programs with demonstrated safety and efficacy. Their lead immunology asset, Gusacitinib (ASN002), is entering Phase 3 development for atopic dermatitis and has shown positive results in Phase 2b for chronic hand eczema. Their lead oncology asset (ASN007/ERAS-007) completed Phase 1 trials in cancer patients with multiple objective responses including complete and partial regression of target lesions. ASN004, an antibody-drug conjugate targeting 5T4, began Phase 1 trials in 2022 for advanced solid tumors.
- Therapeutic areas
- OncologyImmunologyDermatologyNeurology
- Modalities
- Small moleculesBiologicsAntibody-drug conjugates
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Erasca
Beyond the preview
Go deeper on Asana BioSciences, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asana BioSciences, LLC.